EAACI Congress 2025

Back

13 - 16 June 2025 Glasgow, United Kingdom

OAS-CT1 - Clinical Trials on Airways Diseases

Friday 13 Jun, 15:00 PM - 16:30 PM Glasgow, United Kingdom
13:00 PM - 14:30 PM Your local time

Innovation Hub Oral Abstract Session on Clinical Trials

15:00

Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma

Rekha Chaudhuri (United Kingdom)

15:12

Anti-thymic stromal lymphopoietin CM326 for uncontrolled chronic rhinosinusitis with nasal polyps: a randomized, double-blind, placebo-controlled phase 1b/2a trial

Mu Xian (China)

15:24

Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma Experience Early and Sustained Benefit with Depemokimab in the Randomised, Double-Blind, Parallel-Group, Replicate ANCHOR-1/2 Studies

Joaquim Mullol (Spain)

15:36

Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps overall and in patients with and without co-morbid asthma: results from the phase 3 WAYPOINT study

Brian Lipworth (United Kingdom)

15:48

Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 trial

Luo Zhang (China)

16:00

Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma

Rekha Chaudhuri (United Kingdom)

16:12

PQ Grass induces tolerogenic humoral and cellular immune responses: biomarker results from a pivotal Phase III trial

Janice A Layhadi (United Kingdom)